title: [Clinical manifestation of targeted drugs in individualized therapy of malignant tumors].
authors.forename: Da-tong
authors.initials: DT
authors.lastname: Chu
mesh_terms: D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001549:Benzamides; D003520:Cyclophosphamide / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D016503:Drug Delivery Systems / Q000379:methods*; D066246:ErbB Receptors / Q000235:genetics / Q000378:metabolism; D046152:Gastrointestinal Stromal Tumors / Q000188:drug therapy; D006801:Humans; D000068877:Imatinib Mesylate; D007211:Indoles / Q000627:therapeutic use; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy; D007951:Leukemia, Myeloid / Q000188:drug therapy; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy; D009154:Mutation; D009369:Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism; D010879:Piperazines / Q000627:therapeutic use; D011241:Prednisone / Q000627:therapeutic use; D011743:Pyrimidines / Q000627:therapeutic use; D011758:Pyrroles / Q000627:therapeutic use; D012074:Remission Induction; D000069283:Rituximab; D000077210:Sunitinib; D014750:Vincristine / Q000627:therapeutic use
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D001549:Benzamides; D007211:Indoles; D010879:Piperazines; D011743:Pyrimidines; D011758:Pyrroles; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D000068877:Imatinib Mesylate; D003520:Cyclophosphamide; C512478:EGFR protein, human; D066246:ErbB Receptors; D000077210:Sunitinib; D011241:Prednisone